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Sir, 
We read this paper with interest. The publication on the same day of this meta-analysis and our 
article on defining the fracture population in the PROFHER trial1 adds fuel to the debate on the 
interpretation of the results of pragmatic trials such as PROFHER. We suggest that our article,1 the 
trial report2 and a recent ‘User’s guide’ to the medical literature relating to surgical trials featuring 
PROFHER3 provide strong support to the ready applicability of our trial findings. What is the place 
then of the findings and conclusions of Sabharwal et al’s ‘meta-analysis?4 Below, we set out the main 
reasons why their meta-analysis is misconceived and why their conclusions, presented so boldly in 
their title, are invalid. 
Inadequate selection of outcomes and presentation of the evidence. The selection of the four 
outcomes provides an incomplete and inadequate summary of the evidence. In particular, the 
Constant score reported is the sole measure of functional outcome. The authors do, however, 
acknowledge the validity of the patient-reported measures of function reported by PROFHER and 
more recently performed trials. Similarly selective is the restriction of adverse events to AVN, OA 
and non/malunion. This partiality is even more pronounced where the humeral head is replaced. 
Inappropriate subgroup analyses. The stated virtue of this meta-analysis is being the first meta-
analysis for this comparison that “has used subgroup analysis based on the complexity of fractures 
to compare patient outcomes”. Despite a systematic review and trial literature replete with 
warnings on the dangers of subgroup analyses, the authors have taken a bold approach and in doing 
so have provided a misleading picture of the evidence. The selection a priori of subgroup variables is 
a recognised strength, but the classification of a subgroup variable based on a 50% predominance 
threshold for mixed fracture populations is misconceived, and confounding is unavoidable. The 
authors have also failed to recognise the limitations of summary data and to accept that the data are 
just not sufficient to support a valid subgroup analysis based on fracture type. Nor have they noted 
that the subgroup analyses presented for the PROFHER trial split between one- and two-part 
versus three- and four-part (or involvement or not of the tuberosities) do not indicate a difference in 
treatment effect (patient-reported function measured via the Oxford Shoulder Score) in the 
different subgroups.2 
Incorrect interpretation of the results. Caution is required in the interpretation of the meta-analysis 
and even more so in the interpretation of subgroup analyses, the individual subgroup results 
inevitably being based on a reduced sample size. Having judged using GRADE the quality of the 
evidence for the overall analyses to be ‘low’ for health utility or ‘very low’ for the other three 
outcomes, this raises the question why the authors thought that it was safe to present the results for 
subgroups as evidence for underpinning their conclusion. This is particularly questionable for the 
health utility data favouring replacement surgery that are from one trial of 49 participants with four-
part fractures. 
Although there are other errors, such as faulty reporting in the PRISMA diagram, that serve to 
undermine our confidence in the conduct and reporting of this review, we have kept our focus in this 
letter on the key flaws that invalidate the conclusions. Given the serious flaws in the conduct and 
reporting of the review, it is particularly unfortunate that their unsubstantiated conclusion is 
expressed in a headline-grabbing title. 
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